<DOC>
	<DOCNO>NCT00849316</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study investigate clinical safety profile effectiveness use SC NovoRapid™ ( insulin aspart ) patient coexist diabetes kidney disease normal clinical practice condition India .</brief_summary>
	<brief_title>Safety Efficacy Study NovoRapid™ Patients With Coexisting Diabetes Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Any subject coexisting kidney disease type 1 type 2 diabetes eligible study , include : newlydiagnosed subject , insulin naïve subject receive insulin insulin analogue Subjects kidney disease ( stage IIV ) include transplant patient eligible study , initiate NovoRapid™ '' Subjects unlikely comply protocol requirement , e.g. , uncooperative attitude , inability return final visit Subjects stage V chronic kidney disease Subjects previously enrol study Known suspect allergy trial product ( ) relate product</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>